RPRD will expand the availability of its PGx testing services to South Korea, and Orient Bio will diversify its business to include precision medicine and clinical PGx.
A new company, Wamberg Genomic Advisors, launched last week, hoping to provide a conduit to genomic testing through the insurance and employee benefit marketplaces.
The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
